A recent analysis highlights how potential gene therapies have the potential to dramatically reduce income disparities for patients with sickle cell disease, leading to as much as $21,000 more in average income in the year following gene therapy administration alone.
Sickle cell disease is a rare blood disorder that disproportionately affects Black Americans. The disease causes crescent-shaped blood cells to clog blood vessels, which prevents the normal flow of nutrition and oxygen throughout the body and can lead to serious complications, including pain crisis and acute chest syndrome.
Patients with sickle cell disease are hospitalized more than once a year, on average, and visit the emergency room 2 to 3 times a year, most commonly due to pain crisis. For people living with sickle cell disease, 50% report pain on half of their days and 30% report pain most of the time.
50% to 60% of patients reported the disease negatively impacted their employment status, forced them to stop working completely or take a leave of absence, or led to unpaid time off or reduced work hours. As a result, patients are estimated to earn $750,000 less over a lifetime, representing a significant burden on the Black and African American community disproportionately impacted by this disease.
There are 30 medicines in development for sickle cell disease. That list includes gene therapies in the late stages of development that have shown evidence in clinical trials of an almost complete reduction in painful vaso-occlusive crisis as well as acute chest syndrome in the years following a one-time administration of therapy.
Reducing these serious complications can help restore the quality of life in people with sickle cell disease and enable people to maintain more consistent and reliable employment, dramatically reducing income disparities. And the full value of gene therapies may only be realized over a patient’s lifetime. That’s why these groundbreaking therapies requires a rethinking of the way we pay for medicines to account for the long-term value these therapies provide.
Learn more by viewing the report and fact sheet here.
Katie Koziara
Katie Koziara is Senior Director of public affairs at PhRMA focusing on the organization’s executive visibility work and media relations strategy. She previously ran the social media strategy for a D.C.-based non-profit working on federal management and leadership issues. Katie earned her B.A. in Public Policy from the University of Michigan’s Ford School and is currently earning her M.A. in Fiction Writing from Johns Hopkins University.
Katie Koziara
World Sickle Cell Day: Recognizing the promise of gene therapy
New report shows promising pipeline for cell and gene therapies, but access challenges persist
The Patient Perspective: Vaccines
Recent events highlight progress on health equity
ICYMI: PhRMA’s 4th Annual Pathways to Success: Virtual STEM Career Expo
Hispanic Heritage Month: Fighting for Hispanic patients
New Report: Tackling chronic conditions with preventive treatment
PhRMA awards grants to 2024 Annual Pathways to Success: Virtual STEM Career Expo Partners
New Report: Vaccines continue to drive improved health outcomes
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
How government price setting fails to address systemic health care inequities
Women’s Health Month: A conversation with Sage
Championing cancer equity: Our drive for healthier AANHPI communities
New analysis: Accelerated approval pathway is changing lives in underserved communities
PhRMA provides grant funding to support the Morehouse School of Medicine Satcher Health Leadership Institute’s Health Equity Tra
New Report: 1,600 cancer treatments and vaccines in clinical development
New social determinants of health simulation explores structural barriers patients face accessing and affording medicines
Incomplete evaluations undermine patient access to transformational medicine
PhRMA awards grants to 2023 Annual Pathways to Success Graduate Summit Partners
Watch: New video series spotlights advances in biopharmaceutical science
Between hope and despair: Improving cancer outcomes
Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation
Support for continued progress is critical for pediatric drug development
PhRMA awards grant to Emerson Diversity Health Foundation
PhRMA Otorga Beca a la “Emerson Diversity Health Foundation”
New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans
State policymakers can protect American innovation and help Americans live longer, healthier lives
Recognizing National Glaucoma Awareness Month
New Report More than 160 medicines in development for mental illness
ICYMI: Cancer death rate continues to decline due to treatment advances
Using traditional HTAs to determine coverage threatens patient access to medicine
Traditional HTAs keep diverse patients out of the conversation
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
Traditional HTA methods treat everyone like the “average” patient
New Report: Nearly 800 medicines in development to treat chronic conditions
Recognizing National Sickle Cell Awareness Month
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free
Gene therapies can reduce treatment burden and costs for patients with blood disorders
Report: More than 500 medicines in development to treat disorders of the blood
Stephanie Dyson of BMS on reducing health disparities
Report: More than 600 medicines in development for diseases affecting women
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
New Report: Nearly 800 new medicines in development to treat rare diseases
Announcing CAREs Grant Round 4
Announcing CAREs Grant Round 4
Guest post: Continued research and development is critical for ALS patients and families
New report shows more than 260 medicines in development to fight neurodegenerative diseases
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
PhRMA awards $75,000 to fund initiatives to reduce health inequities
Watch: Building trust and enhancing clinical trial diversity
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
PhRMA hosts first stakeholder workshop on clinical trial diversity
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections
PhRMA member companies share how they are improving clinical trial diversity
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
Paper finds gaps in health data are a barrier to health equity
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
Increasing diversity at investigator sites could increase minority participation in clinical trials
Report highlights biopharmaceutical industry’s commitment to D&I
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
Report: More than 1,300 medicines and vaccines in development to help fight cancer
PhRMA CAREs Grant request for proposals: Addressing racial disparities in medication utilization and adherence
Committing to diversity, equity and inclusion: A call to action for clinical trials
Just released: PhRMA members’ new clinical trial diversity principles
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
Guest Post: Honoring Hispanic Heritage Month by taking action on health equity
Sharing rebates can improve access to medicines and increase health equity
PhRMA will continue to advocate for equity within our industry
Three ways the pharmaceutical industry can positively impact health equity
Guest Post: Amgen Foundation stands for equal opportunities in STEM learning
Systemic racism is as real as any disease, and our industry is not immune
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
PhRMA awards $100,000 to fund projects that address health inequalities
Observing National Minority Health Month in the age of COVID-19
New report shows nearly 260 vaccines in development, including dozens for COVID-19
Nearly 400 cell and gene therapies in development to target a broad range of diseases
Nearly 140 medicines in development to treat mental illness
New report shows more than 160 medicines in development for diabetes and related conditions
New report shows nearly 20 innovative medicines in development for sickle cell disease
130 medicines in development for asthma, allergies and other respiratory diseases
130 medicines in development for asthma, allergies and other respiratory diseases
New report shows nearly 300 cell and gene therapies in development
World AIDS Day 2018: Hope for the future
New report shows more than 300 skin disease medicines in development
New report details the setbacks and challenges to Alzheimer’s research
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
A new era in Alzheimer’s innovation
New report shows over 500 medicines in development for neurological disorders
Guest post: Advancing healthy hearts for patients
New report shows 200 medicines in development for heart disease and stroke
World AIDS Day 2017: Scientific breakthroughs paving the way for an AIDS-free generation
2017 Research & Hope Awards honor innovators in mental health
Medicare Monday: Strengthening access to vaccines for seniors
Finding cures for incurable diseases
New report portrays flourishing pipeline
More than 50 medicines and vaccines in development for HIV infection, treatment and prevention
Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines
More than 240 immuno-oncology treatments in development to fight cancer
Significant progress fighting cancer: Death rate has dropped 25 percent
3 things to know about 2016 drug approvals
Potential gene therapies bring hope to patients with sickle cell disease
Medicines in Development
Health Equity
Cell and Gene Therapy
Potential gene therapies bring hope to patients with sickle cell disease
Potential gene therapies bring hope to patients with sickle cell disease